RS Research Announces Online Abstract Acceptance at the 2025 ASCO Annual Meeting
15 June 2025
RS Research, a clinically-validated biotechnology company developing targeted oncology therapies with a focus on improved safety and efficacy, announced that an abstract presenting the Phase 1a clinical trial results of its lead candidate, RS_0139, has been accepted for online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL.
RS Research is advancing Sagitta® smart nanomedicines and clinically validated polymer-drug conjugates (PDC) to overcome the traditional efficacy-toxicity trade-off of cytotoxic therapies. The Sagitta® platform enables targeted delivery of cytotoxic and radiolabeled payloads via tunable linkers and ligands, allowing selective accumulation of therapeutic agents in tumor tissue. This approach results in improved pharmacokinetic profiles, enhanced therapeutic index, and reduced systemic toxicity. The platform is supported by integrated, in-house GMP manufacturing, enabling rapid CMC development and scale-up.
RS-0139 is RS Research’s lead clinical candidate and is currently being evaluated in Phase I clinical trial. The investigational therapy is designed to deliver docetaxel selectively to integrin receptor-expressing solid tumors.
The abstract reports results from the Phase 1a dose-escalation study, which successfully identified a safe and tolerable dose range for RS-0139. The study represents an important milestone in the clinical development of the Sagitta® platform.
Abstract Title: Phase 1a dose-escalation study of RS-0139: A novel tumor-targeted nanomedicine for advanced solid tumors
Date: 30 May – 03 March 2025
Location: McCormick Place | Chicago, IL
The abstract is available online via the ASCO website.
About RS Research (as of Q3 2025)
RS Research is a clinical-stage biotechnology company developing targeted oncology medicines using its proprietary Sagitta® nanomedicine platform. The company’s lead asset, RS-0139, has completed Phase 1a and is currently in Phase 1b clinical development with a differentiated safety profile. The pipeline is further expanded with RS-0625, a dual-payload smart chemotherapy candidate, and RS-0826, a radiotheranostic program. With EMA SME status and integrated GMP manufacturing capabilities, RS Research is positioned to advance a portfolio of safer and more effective therapies for solid tumors.
For detailed information:
For media inquiries: pr@rsresearch.net
For scientific inquiries: medicalinformation@rsresearch.net
www.rsresearch.net
